Spleens of myelofibrosis patients contain malignant hematopoietic stem cells
Open Access
- 1 October 2012
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 122 (11), 3888-3899
- https://doi.org/10.1172/jci64397
Abstract
Cancer stem cell behavior is thought to be largely determined by intrinsic properties and by regulatory signals provided by the microenvironment. Myelofibrosis (MF) is characterized by hematopoiesis occurring not only in the marrow but also in extramedullary sites such as the spleen. In order to study the effects of these different microenvironments on primitive malignant hematopoietic cells, we phenotypically and functionally characterized splenic and peripheral blood (PB) MF CD34+ cells from patients with MF. MF spleens contained greater numbers of malignant primitive HPCs than PB. Transplantation of PB MF CD34+ cells into immunodeficient (NOD/SCID/IL2Rγnull) mice resulted in a limited degree of donor cell chimerism and a differentiation program skewed toward myeloid lineages. By contrast, transplanted splenic MF CD34+ cells achieved a higher level of chimerism and generated both myeloid and lymphoid cells that contained molecular or cytogenetic abnormalities indicating their malignant nature. Only splenic MF CD34+ cells were able to sustain hematopoiesis for prolonged periods (9 months) and were able to engraft secondary recipients. These data document the existence of MF stem cells (MF-SCs) that reside in the spleens of MF patients and demonstrate that these MF-SCs retain a differentiation program identical to that of normal hematopoietic stem cells.Keywords
This publication has 44 references indexed in Scilit:
- The mesenchymal tumor microenvironmentCell Adhesion & Migration, 2012
- Differential Mechanical Response of Mesenchymal Stem Cells and Fibroblasts to Tumor-Secreted Soluble FactorsPLOS ONE, 2012
- Splenic extramedullary hematopoietic proliferation in Philadelphia chromosome-negative myeloproliferative neoplasms: heterogeneous morphology and cytological compositionLaboratory Investigation, 2012
- Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient miceJCI Insight, 2011
- Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cellsBlood, 2010
- How the niche regulates hematopoietic stem cellsChemico-Biological Interactions, 2010
- Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasmsExperimental Hematology, 2009
- Hematopoietic niche and bone meetCurrent Opinion in Supportive & Palliative Care, 2008
- Erlotinib Effectively Inhibits JAK2V617F Activity and Polycythemia Vera Cell GrowthJournal of Biological Chemistry, 2007
- Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosisBlood, 2006